Permanent125 I prostate brachytherapy for stage C hormone refractory prostate cancer

Fan Zhang,Yi Huang,Lulin Ma,Junjie Wang,Weiqiang Ran
2010-01-01
Abstract:Objective: To evaluate the clinical efficacity of permanent125 I prostate brachytherapy in patients with stage C hormone refractory prostate cancer. Methods: A total of 11 patients with prostate cancer was diagnosed by prostate biopsy, Gleason score of them was 6∼9, average PSA was 10.91ng/ml at the progression to hormone refractory prostate cancer, and clinical staging was C stage. All patients underwent 3-dimensional conformal brachytherapy with transperineal ultrasound-guide l251 seeds prostate implantation. Results None of the patients had any adverse events during the operation processes. The operation time was from 30 to 70 mins and hospital staying time was from 3 to 6 days. The mean number of implanted125 I seeds was 49. All patients were followed up for 3 to 71 months with a mean of 31 months. Of them, 3 cases had complete reaction, 1 partial reaction, 3 stable condition and 3 developed progressive disease(PD), one patient lost during following-up. The survival rate of PSA progression free was 70 % (7/10). For other 3 PD patients, 2 patients' PSA progression free survival time was longer than 2 years. No severe complication occurred in all cases. Conclusion: Brachytherapy with 125I seeds implantation is a safe and effective treatment for patients with stage C hormone refractory prostate cancer.
What problem does this paper attempt to address?